Extreme volatility has been seen consistently in the bio-sectors as seen the chart in the above analysis - NXRP has received consistently positive news regarding their primary drug ZYESAMI and the clinical trials they are actively participating in.
Profile :
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behaviour. The company was founded in 2015 and is based in Wilmington, Delaware.